Human expandable pancreatic progenitor-derived β cells ameliorate diabetes

Area of Science:

• Stem cell biology
• Regenerative medicine
• Endocrinology

Background:

• Human pancreatic beta cells are crucial for diabetes treatment but difficult to source.
• Current methods for generating beta cells from pluripotent stem cells face scalability and cost challenges.

Purpose of the Study:

• To identify chemical compounds that promote the expansion of human pancreatic progenitors.
• To develop a scalable and cost-effective method for producing functional beta cells for therapeutic use.

Main Methods:

• Chemical screening to identify compounds that enhance pancreatic progenitor expansion.
• Utilizing the BET inhibitor I-BET151 to expand PDX1+NKX6.1+ pancreatic progenitors (PPs).
• Assessing the differentiation potential of expanded PPs into functional beta cells (ePP-β cells) and their efficacy in vivo.

Main Results:

• I-BET151 robustly promotes the long-term expansion of pancreatic progenitors (ePPs).
• ePPs efficiently differentiate into functional ePP-β cells.
• Transplantation of ePP-β cells rapidly ameliorated diabetes in mouse models.
• I-BET151 was found to activate Notch signaling and upregulate key progenitor genes.

Conclusions:

• The study achieved robust expansion of pancreatic progenitors, a significant step towards unlimited beta cell supply.
• I-BET151 treatment offers a promising strategy for generating functional beta cells for regenerative medicine.
• Epigenetic and transcriptional modulation is key for lineage-specific progenitor self-renewal.